Raising the Bar in Psoriasis: The Role of TNF Inhibitors

A supplement to Skin & Allergy News supported by an unrestricted educational grant from Amgen and Wyeth.
Highlights of presentations that took place at the 27th Annual Hawaii Dermatology Seminar.

•Contents
•Target Audience
•Educational Needs
•Learning Objectives
•CME Recognition

To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 12.

Contents

Introduction
Mark G. Lebwohl, MD
Professor and Chairman
Department of Dermatology
Mount Sinai School of Medicine
New York
Clinical Grants: Amgen, Wyeth, Centocor, Biogen and Genentech. Consultant: Biogen and Centocor. Discusses the investigational use of infliximab and etanercept for treating psoriasis.

Psoriasis and Hepatitis C: A Case Prevention
Mark G. Lebwohl, MD
Professor and Chairman
Department of Dermatology
Mount Sinai School of Medicine
New York, NY
Clinical Grants: Amgen, Wyeth, Centocor, Biogen and Genentech. Consultant: Biogen and Centocor. Discusses the investigational use of infliximab and etanercept for treating psoriasis.

A Mechanistic Approach to Differentiating Biologic Agents
Ivor Caro, MD
Assistant Professor of Dermatology
Department of Dermatology
Harvard Medical School
Massachusetts General Hospital
Boston
Clinical Grants: Amgen, Centocor, Genentech and Biogen. Consultant: Amgen, Centocor, Genentech and Biogen. Discusses the investigational use of etanercept, infliximab, and efalizumab for treating psoriasis.

Clinical Evidence for the Use of Anti-TNF Therapy in Dermatology Practice
Alice B. Gottlieb, MD, PhD
Director, Clinical Research Center
W.H. Conzen Chair in Clinical Pharmacology
Professor of Medicine, University of Medicine
And Dentistry of New Jersey
Robert Woods Johnson Medical School
New Brunswick
Clinical Grants: Wyeth and Amgen; Consultant: Wyeth and Amgen. She discusses the investigational use of etanercept for the treatment of psoriasis.

Practical Applications of Anti-TNF Therapy in Dermatology Practice
Bernard S. Goffe, MD
Clinical Professor
Department of Medicine
Division of Dermatology
University of Washington School of Medicine
Minor & James Medical PLLC
Seattle
Clinical Grants: Amgen. Discusses the investigational use of etanercept for treating psoriasis.

Target Audience

This activity has been developed for dermatologists and other healthcare professionals involved in the treatment of patients with psoriasis and psoriatic arthritis (PsA).

Educational Needs

Psoriasis and its frequent complication, PsA, can cause considerable morbidity and disability. The availability of new biologic agents that inhibit the proinflammatory cytokine tumor necrosis factor (TNF) represents a major step forward in the safe and effective treatment of both psoriasis and PsA. Dermatologists need to be aware of how TNF-inhibiting drugs work in psoriasis/PsA, what is involved in introducing the use of these agents in the average dermatology practice, and the clinical results that can be expected with anti-TNF therapy.

Learning Objectives

By reading and studying this supplement, participants should be able to:

• Briefly explain the role of TNF in psoriasis and PsA.

• Identify the role that anti-TNF therapy plans in the treatment of psoriasis and PsA.

• Discuss the efficacy of etanercept in PsA, as demonstrated in clinical trials.

• Discuss the safety of anti-TNF therapy, based on the data accumulated for etanercept over a 5- to 6-year period.

CME Recognition

Skin & Allergy News certifies that this educational activity has been recognized for 1 hour of AAD Category 1 CME credit and may be used toward the American Academy of Dermatology's Continuing Medical Education Award.

Term of Approval: May 2003–April 2004.

This program was developed in accordance with the Accreditation Council for Continuing Medical Education guidelines.

Copyright © 2003 by International Medical News Group

---